quadrivalent vaccine

Latest Headlines

Latest Headlines

CSL's Seqirus aims for 'industry leadership' as it integrates Novartis' flu vaccines

Months after its formation last fall, CSL's flu vaccines unit Seqirus is a loss-making entity. However, leadership there believes the operation can achieve "industry leadership" in 5 to 10 years by relying on a move into quadrivalent vaccines, the launch of Fluad and emerging markets growth.

Daiichi Sankyo inks deal to market AstraZeneca's FluMist in Japan


Study: Flublok is more effective than traditional flu shot

Protein Sciences released data showing that Flublok Quadrivalent--its follow-up to the FDA-approved trivalent Flublok--outperformed the traditional egg-based quadrivalent vaccine.

H1N1's dominance this flu season makes quadrivalent vaccines' broader protection moot

The current flu season should have provided the first opportunity to gauge the impact of quadrivalent vaccines. However, the extra B strain in the quadrivalent vaccines has been rendered irrelevant by the almost total dominance of H1N1.

Quadrivalent flu vaccines drive surge in sales at AstraZeneca, GSK and Sanofi

Consumers faced an array of choices going into the current flu season, with quadrivalent vaccines being sold alongside high-dosage varieties and vaccines produced without eggs. Fourth-quarter results suggest people have taken up the new options, with sales at AstraZeneca, GlaxoSmithKline and Sanofi soaring.

CDC warns H1N1 virus is causing severe flu in young adults


GSK shares data from pivotal PhIII trial of quadrivalent flu vaccine

The full effect of the introduction of quadrivalent flu vaccines is unlikely to become clear for several years, but this week saw the release of data that convinced the FDA to approve GlaxoSmithKline's vaccine. And while the benefit of the extra strain is unclear, the data makes a case for immunizing with any flu vaccine.

AstraZeneca eyes 2014 EU launch for 4-in-1 flu vaccine after winning approval

When MedImmune won approval for its quadrivalent nasal flu vaccine back in February 2012, it kicked off the battle to claim a share of the next-generation influenza immunization market. Now, almost two years later, its parent company AstraZeneca has the race underway in Europe, too.